MyBlueDotsMeiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy MyBlueDots4 months ago01 mins TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma invests in MPM BioImpact’s new technology and virology strategy to expand early-stage opportunities and enhance the global network. Go to Source Author: Post navigation Previous: Amylyx Pharmaceuticals Announces Proposed Public Offering of Common StockNext: Yagi & Co., Ltd.: New Material “LAVATECH” Containing Lava from Mt. Fuji to Be Exhibited at Heimtextil 2025
An overlooked cell type orchestrates brain rewiring during states of heightened attention MyBlueDots3 days ago 0
Violence between parents or in the community increases risk of child punishment MyBlueDots3 days ago 0
Genome mapping of Brazil’s diverse population uncovers new variants linked to health MyBlueDots3 days ago 0